Landscape Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$644K Buy
+14,429
New +$820K 0.05% 379
2026
Q2
– Sell
-20,146
Closed -$1.51M – 768
2026
Q1
$1.51M Sell
20,146
-4,009
-17% -$316K 0.1% 308
2025
Q4
$1.91M Sell
24,155
-2,407
-9% -$181K 0.13% 242
2025
Q3
$1.74M Buy
+26,562
New +$1.3M 0.11% 267
2025
Q1
– Sell
-10,270
Closed -$359K – 749
2024
Q4
$359K Sell
10,270
-15,165
-60% -$567K 0.04% 476
2024
Q3
$1.02M Buy
+25,435
New +$1.18M 0.1% 260
2019
Q3
– Sell
-13,605
Closed -$874K – 729
2019
Q2
$874K Hold
13,605
– – 0.07% 305
2019
Q1
$1.1M Sell
13,605
-716
-5% -$46.2K 0.1% 228
2018
Q4
$774K Buy
+14,321
New +$730K 0.06% 327
2018
Q3
– Sell
-7,154
Closed -$298K – 744
2018
Q2
$298K Buy
+7,154
New +$317K 0.02% 391

Other funds holding IONS

Landscape Capital Management's IONS Position: Q3 2026 in Review

Landscape Capital Management opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2026: 14,429 shares worth $644K. The stake represents 0.05% of the portfolio and ranks #379 among its holdings. This is a return to the name: Landscape Capital Management previously reported a position in IONS as recently as Q1 2026.

Landscape Capital Management first reported a position in IONS in Q2 2018 and has held it in 10 quarters since. The position peaked at $1.91M in Q4 2025. 458 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Landscape Capital Management held 14,429 shares of Ionis Pharmaceuticals worth $644K as of Q3 2026.
  • Ionis Pharmaceuticals was a new Landscape Capital Management position in Q3 2026.
  • Ionis Pharmaceuticals made up 0.05% of Landscape Capital Management's portfolio in Q3 2026, its #379 holding.
  • Landscape Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2018 and has held it in 10 quarters since.
  • Landscape Capital Management's Ionis Pharmaceuticals position peaked at $1.91M in Q4 2025.
  • 458 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Landscape Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.